The effect of a tyrosine kinase inhibitor on endotoxin mortality and splenocyte mediator production in the neonatal rat

Shock

Volumn 11, Issue 1, 1999, Pages 35-38

  Cochran, Joel B ^a   Genovese, Francesco ^b   Romeo, Christina ^b   Guyton, Kelly ^c   Teti, Guiseppe ^b   Cook, James A ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF MESSINA   (Italy)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; LYMPHOKINE; PROTEIN TYROSINE KINASE;

ANIMAL; ARTICLE; BIOSYNTHESIS; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; MORTALITY; NEWBORN; PHYSIOLOGY; PREGNANCY; RAT; SEPTIC SHOCK; SPLEEN; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; ANIMALS, NEWBORN; ENDOTOXINS; FEMALE; LYMPHOKINES; PREGNANCY; PROTEIN-TYROSINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; SHOCK, SEPTIC; SPLEEN; TIME FACTORS;

EID: 0032607498     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199901000-00005     Document Type: Article

References (24)

1. Cairo MS: Neonatal neutrophil host defense: Prospects for immunologic enhancement during neonatal sepsis. Am J Dis Child 143:40-46, 1986.
2. Hill HR: Diagnosis and treatment of sepsis in the neonate. In Root RK Sande MA (eds): Septic Shock. New York: Churchill Livingstone, Inc., 1985, pp 219-232.
3. Zeller WP, Goto M, Witek-Hanusek L, Hurley RM: Mortality, temporal substrate and insulin responses to endotoxic shock in zero, ten and twenty-eight day old rats. Surg Gynecol Obstet 173:375-383, 1991.
4. Zeligs BJ, Armstrong CD, Walser JB, Bellanti JA: Age-dependent susceptibility of neonatal rats to Group B streptococcal type III infection: Correlation of severity of infection and response of myeloid pools. Infect Immun 37:255-263, 1982.
5. Cochran JB, Chen H, LaVia M, Cusumano V, Teti G, Cook JA: Age-related mortality and adherent splenic cell mediator production to endotoxin in the rat. Shock 4:450-454, 1995.
6. Bone RC, Balk RA, Fein AM, et al: A second large controlled study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 23:994-1006, 1995.
7. Opal SM, Fischer CJ, Dhainaut JFA: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 25:1115-1124, 1997.
8. Reinhart K, Weigand-Lohnert C, Grimminger F: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody fragment, MAK 195, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose ranging study. Crit Care Med 24: 733-742, 1996.
9. Dhainaut JFA, Vincnet JL, Richard C: CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmokinetics, immune response and influence of the antibody on cytokine concentration in patients with septic shock. Crit Care Med 23:1461-1469, 1995.
10. Sevransky JE, Shaked G, Novogrodsky A, et al: Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine Escherichia coli peritonitis. J Clin Invest 99:1966-1973, 1997.
11. Orlicek SL, Meals E, English BK: Differential effects of tyrosine kinase inhibitors on tumor necrosis factor and nitric oxide production by murine macrophages. J Infect Dis 174:639-642, 1996.
12. Vanichkin A, Patya M, Lazit A, Levitzki A, Novogrodsky A: Late administration of a lipophilic tyrosine kinase inhibitor prevents lipopolysaccharide and Escherichia coli induced lethal toxicity. J Infect Dis 173:927-933, 1996.
13. Novogrodsky A, Vanichkin A, Patya M, Gazit A, Osherov W, Levitzki A: Prevention of lipopolysaccharide induced lethal toxicity by tyrosine kinase inhibitors. Science 264:1319-1322, 1994.
14. Burch RM, Knapp DR, Haluska PV: Vasopressin stimulates thromboxane synthesis in the toad urinary bladder: Effects of imidazole. J Pharmacol Exp Ther 210:344-348, 1979.
15. Wise WC, Cook JA, Eller T, Halushka PV: Ibuprofen improves survival from toxic shock in the rat. J Pharmacol Exp Ther 215:160-164, 1980.
16. Fitzgerald M, Zeller WP, Goto M, Anderson CL, Hurley RM: Concurrent clinical and metabolic derangements in the newborn rat: A late phase sepsis model. Ann Clin Lab Sci 18:229-234, 1988.
17. Uhr JW: The effect of bacterial endotoxin on the newborn guinea pig. J Exp Med 115:685-694, 1962.
18. Ogura S, Umegaki O, Cochran JB, Halushka PV, Cook JA: Effects of tyrphostin AG 556 on rat shock induced by cecal ligation puncture or LPS. Shock 9 (suppl 1) 33:1998.
19. Umegaki O, Cook JA, Ogura S: Tyrphostin AG 556, a tyrosine kinase inhibitor, has protective effects on Gram-positive sepsis in rats. Shock 9 (suppl 1):37, 1998.
20. Ogura S, Genovese F, Cochran JB, Halushka PV, Cook JA: Effect of a tyrosine kinase inhibitor on production of macrophage mediators induced by Group B streptococcus or endotoxin. Shock 7(suppl 2):50, 1997.
21. Ruetten H, Thiemermann C: Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: a possible role for protein tyrosine kinase. Br J Pharm 122:59-70, 1997.
22. Kilbourn RG, Szabo C, Traber DL: Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: Lessons learned from experimental and clinical studies. Shock 7:235-246, 1997.
23. Lopez-Talavera JC, Levitzki A, Martinez M, Gazit A, Esteban R, Guardia J: Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreased nitric oxide production in cirrhotic rats with portal hypertension and ascites. J Clin Invest 100:664-670, 1997.
24. Cusumano V, Mancuso G, Genovese F, et al: Neonatal hypersusceptibilty to endotoxin correlates with increased tumor necrosis factor production in mice. J Infect Dis 176:168-176, 1997.